Patients are frequently the last to know when the FDA quietly withdraws a blood pressure medication.
This story has a subtle unnerving quality. Every morning, you take your medication at the same time, with the same glass of water, following the same routine, and you have faith that the ingredients in the bottle are working as intended. A notice is then sent out a few weeks or months later. The medication wasn’t functioning as intended. It was never the case. And nobody gave you a call.
Patients who were prescribed Chlorthalidone tablets, USP 25 mg, a common diuretic for high blood pressure, essentially faced that circumstance. After long-term stability testing showed that the tablets did not meet dissolution requirements, the FDA announced a nationwide recall of about 11,460 bottles. Put simply, the medication may not have entered the bloodstream as intended because the pills may not have dissolved properly in the body.
Dissolution testing is more than just checking a box. It’s the type of quality metric that indicates whether a drug behaves like a drug after ingestion. A tablet may pass through the body without administering its entire dose if those outcomes are insufficient. That treatment gap may go unnoticed for a long time for someone managing high blood pressure, a condition that seldom manifests symptoms.
Batch numbers RISA24001 and RISB24002, which have an expiration date of April 2027, are on the recalled bottles. They were produced in India by Inventia Healthcare Limited and distributed by New Jersey-based Rising Pharma Holdings, Inc. Although the stability testing that led to the recall had reportedly been going on for about 18 months, the recall was actually started on June 5. That timeline begs the question, “How long were these bottles sitting in homes and pharmacies while testing was still ongoing?”
It’s important to remember that this isn’t the worst kind of recall. However, that classification is only somewhat consoling. A drug that dissolves improperly is problematic in a more subtle, long-term way rather than being hazardous in the immediate sense. Even if nothing significant occurs today, a patient whose blood pressure isn’t adequately controlled will eventually be at increased risk.
The timing makes this more difficult to ignore. Amlodipine and Olmesartan Medoxomil, two more blood pressure drugs, were recalled for the same reason just one month prior in May. failed to meet the requirements for dissolution. In that case, over 15,000 bottles were pulled. Within weeks of one another, there were two distinct recalls involving two different manufacturers and the same fundamental problem. It’s difficult to ignore that pattern.
How much of what is dispensed at retail pharmacies is made abroad, under what supervision, and tested to what standards before it reaches someone’s kitchen counter? This is part of a larger discussion that the industry rarely has loud enough. The majority of people don’t consider the source of their generic drugs. Perhaps a lot of people would be shocked to learn. Nowadays, the great majority of prescriptions filled in the US are generic, and a sizable chunk of the supply chain passes through Chinese and Indian manufacturers.
Nothing about that is intrinsically frightening. Many pharmaceuticals made overseas are effective, safe, and well-tested. However, recalls such as this one, which occur twice in the same drug category during the same season, do raise concerns about whether current quality controls are detecting issues early enough or only later.
For the time being, patients taking chlorthalidone should contact their pharmacist or prescribing doctor and compare the batch number on their bottle to the FDA’s recall notice. Since stopping a blood pressure medication suddenly carries risks of its own, the medication should not be simply stopped without guidance. The useful guidance is fairly simple. However, it is more difficult to address the wider discomfort over the phone.
